Charles River, Captain T Cell in plasmid DNA-Viral Vector alliance

Charles River Laboratories International and Captain T Cell, a spinoff from the renowned Max Delbruck Center Berlin, Germany, announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy CGT Accelerator Program CAP , Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization CDMO capabilities and advisory services ahead of Captain T Cell’s plan to manufacture a TCR-T cell therapy for solid tumor patients for a Phase I clinical trial….With the goal to give new patient groups access to T cell immunotherapies, Captain T Cell is developing efficacy-enhanced treatment options for solid tumor therapies. Using a toolbox of next-generation technologies, Captain T Cell generates T cells displaying tumor-specific T cell receptors TCR as well as enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. Once infused into a patient’s body, these tumor-specific T cells intend to find and destroy tumor cells. This therapeutic method may provide an option for patients with tumors that no longer respond to other therapies. “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy. Charles River has decades of success reliably manufacturing plasmid DNA, viral vectors, and cell therapies, helping to safeguard our customer programs and bring potential therapies to patients with limited options.” – Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River